Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-14-2759 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-14-2759 C4490180!4490180!25779943     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2015 ; 21 (18): 4174-83 Nephropedia Template TP {{tp|p=25779943|t=2015. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing |pdf=|usr=}}{{25779943}} gab.com Text Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25779943 #FOAvip Purpose: Mounting evidence supports the clinical significance of gene mutations and immunogenetic features in common mature B-cell malignancies. Experimental Design: We undertook a detailed characterization of the genetic background of splenic marginal zone lymphoma (SMZL), using targeted re-sequencing and explored potential clinical implications in a multinational cohort of 175 SMZL patients. Results: We identified recurrent mutations in TP53 (16%), KLF2 (12%), NOTCH2 (10%), TNFAIP3 (7%), MLL2 (11%), MYD88 (7%) and ARID1A (6%), all genes known to be targeted by somatic mutation in SMZL. KLF2 mutations were early, clonal events, enriched in patients with del(7q) and IGHV1-2*04 B-cell receptor immunoglobulins, and were associated with a short median time-to-first-treatment (0.12 vs. 1.11 yrs; P=0.01). In multivariate analysis mutations in NOTCH2 (HR 2.12, 95%CI 1.02-4.4, P=0.044) and 100% germline IGHV gene identity (HR 2.19, 95%CI 1.05-4.55, P=0.036) were independent markers of short time-to-first-treatment, while TP53 mutations were an independent marker of short overall survival (HR 2.36, 95% CI 1.08-5.2, P=0.03). Conclusion: We identify key associations between gene mutations and clinical outcome, demonstrating for the first time that NOTCH2 and TP53 gene mutations are independent markers of reduced treatment-free and overall survival, respectively. Twit Text FOAVip Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25779943 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25779943 #FOAvip English Wikipedia <ref>{{Cite pmid|25779943}}</ref> Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing #MMPMID25779943 Parry M; Rose-Zerilli MJ; Ljungström V; Gibson J; Wang J; Walewska R; Parker H; Parker A; Davis Z; Gardiner A; McIver-Brown N; Kalpadakis C; Xochelli A; Anagnostopoulos A; Fazi C; de Castro DG; Dearden C; Pratt G; Rosenquist R; Ashton-Key M; Forconi F; Collins A; Ghia P; Matutes E; Pangalis G; Stamatopoulos K; Oscier D; Strefford JC Clin Cancer Res 2015[Sep]; 21 (18): 4174-83 PMID25779943show ga Purpose: Mounting evidence supports the clinical significance of gene mutations and immunogenetic features in common mature B-cell malignancies. Experimental Design: We undertook a detailed characterization of the genetic background of splenic marginal zone lymphoma (SMZL), using targeted re-sequencing and explored potential clinical implications in a multinational cohort of 175 SMZL patients. Results: We identified recurrent mutations in TP53 (16%), KLF2 (12%), NOTCH2 (10%), TNFAIP3 (7%), MLL2 (11%), MYD88 (7%) and ARID1A (6%), all genes known to be targeted by somatic mutation in SMZL. KLF2 mutations were early, clonal events, enriched in patients with del(7q) and IGHV1-2*04 B-cell receptor immunoglobulins, and were associated with a short median time-to-first-treatment (0.12 vs. 1.11 yrs; P=0.01). In multivariate analysis mutations in NOTCH2 (HR 2.12, 95%CI 1.02-4.4, P=0.044) and 100% germline IGHV gene identity (HR 2.19, 95%CI 1.05-4.55, P=0.036) were independent markers of short time-to-first-treatment, while TP53 mutations were an independent marker of short overall survival (HR 2.36, 95% CI 1.08-5.2, P=0.03). Conclusion: We identify key associations between gene mutations and clinical outcome, demonstrating for the first time that NOTCH2 and TP53 gene mutations are independent markers of reduced treatment-free and overall survival, respectively. äGenetics and Prognostication in Splenic Marginal Zone Lymphoma: Revela(epmc).pdf DeepDyve Pubget Overpricing